ASTELLAS PHARMA A/S: Financial statements 2018
CVR: 10888638
Source: annual report 2018, Danish Business Authority
01/04/2017 – 31/03/2018
ASTELLAS PHARMA A/S (CVR 10888638) has filed annual accounts for 2018. In 2018, the company reported revenue of EUR 157,806,000 and a net result of EUR 2,562,000 compared with EUR 12,189,000 the year before. That is an increase of 8.9% compared with the year before. The profit margin was 1.6%. Equity in the 2018 report amounted to EUR 54,102,000. The solvency ratio was 52.4%. The company had 115 employees in the financial year.
- Revenue
- EUR 157,806,000
- Gross Profit
- EUR 20,491,000
- Profit/Loss
- EUR 2,562,000
- Equity
- EUR 54,102,000
- Total Assets
- EUR 103,234,000
- Employees
- 115
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | 157.8 mio. EUR | 20.5 mio. EUR | 2.6 mio. EUR | 54.1 mio. EUR | 115 |
| 2017 | 144.9 mio. EUR | 17.9 mio. EUR | 12.2 mio. EUR | 51.5 mio. EUR | 117 |
| 2016 | 156 mio. EUR | - | 6.7 mio. EUR | 45.4 mio. EUR | 118 |
| 2015 | 121.9 mio. EUR | 25.8 mio. EUR | 5.3 mio. EUR | 38.7 mio. EUR | 116 |
| 2014 | 97 mio. EUR | 26.5 mio. EUR | 7 mio. EUR | 38.4 mio. EUR | 112 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationAbout ASTELLAS PHARMA A/S
ASTELLAS PHARMA A/S is a Danish company of the type Aktieselskab based in København S, founded in 1987. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named YAMANOUCHI PHARMA A/S and BROCADES PHARMA A/S. The management consists of Mark Andree Dekker. The board consists of Damla Ebru Atilgan (chair), Anne Nymand, Giuseppe Maduri and Mark Andree Dekker. The company is owned by Astellas Pharma Europe LTD.. The company has 67 employees (2026). In 2026, the company reported revenue of EUR 197,863,000 and a net result of EUR 5,229,000 compared with EUR 5,705,000 the year before. Equity in the 2026 report amounted to EUR 20,071,000.